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Abstract: Preclinical and clinical tomographic imaging systems increasingly are being utilized for non-invasive imaging 
of reporter gene products to reveal the distribution of molecular therapeutics within living subjects. Reporter gene and 
probe combinations can be employed to monitor vectors for gene, viral, and cell-based therapies. There are several re-
porter systems available; however, those employing radionuclides for positron emission tomography (PET) or single-
photon emission computed tomography (SPECT) offer the highest sensitivity and the greatest promise for deep tissue im-
aging in humans. Within the category of radionuclide reporters, the thyroidal sodium iodide symporter (NIS) has emerged 
as one of the most promising for preclinical and translational research. NIS has been incorporated into a remarkable vari-
ety of viral and non-viral vectors in which its functionality is conveniently determined by in vitro iodide uptake assays 
prior to live animal imaging. This review on the NIS reporter will focus on 1) differences between endogenous NIS and 
heterologously-expressed NIS, 2) qualitative or comparative use of NIS as an imaging reporter in preclinical and transla-
tional gene therapy, oncolytic viral therapy, and cell trafficking research, and 3) use of NIS as an absolute quantitative re-
porter. 
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INTRODUCTION 
  Advances in preclinical and clinical tomographic imaging 
systems have enabled non-invasive imaging of reporter gene 
products to reveal the temporal and spatial biodistribution of 
molecular therapies in virtually any location within living 
subjects. Imaging of molecular therapies is critical to our 
understanding of patient-to-patient variability in treatment 
response, the development of new treatment strategies, and 
for patient safety monitoring. The three most common re-
porter gene imaging approaches use genes that encode an 
enzyme, receptor, or transport protein, and each of these ap-
proaches has its strengths and weaknesses [1, 2]. Ironically, 
one of the oldest examples of an imaging reporter gene in 
humans, the sodium iodide symporter (NIS), has emerged as 
one of the most exciting and promising reporter genes in 
preclinical and translational research. NIS is normally ex-
pressed on the basolateral surface of thyroid follicular cells 
and mediates uptake of plasma iodide (its physiologic sub-
strate). In addition to iodide, NIS has the ability to transport 
several other atoms or molecules including perchlorate, per-
rhenate, astatide, tetrafluoroborate, and pertechnetate.  
  There have been many excellent review articles on NIS 
published over the past 10 years [3-23]. These articles de-
scribe in great detail the molecular structure, function, and 
regulation of NIS, particularly as it applies to imaging and 
therapy of the normal and diseased thyroid gland. This re-
view will provide a basic overview of the structure and func-
tion of NIS, but will focus on 1) differences between   
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endogenous NIS and heterologously-expressed NIS, 2) quali-
tative or comparative use of NIS as an imaging reporter to 
monitor temporal and spatial vector distribution in preclini-
cal and translational gene therapy, oncolytic viral therapy, 
and cell trafficking research, and 3) the use of NIS as a sensi-
tive and quantitative reporter to determine the number of 
vector-engaged cells in a given volume of tissue. 
STRUCTURE, FUNCTION AND REGULATION OF 
NIS IN THE THYROID 
  The biosynthesis of thyroid hormones has been exten-
sively described in medical textbooks and in the literature [5, 
24, 25]. The following is a brief summary of the role of NIS 
in that process. NIS is an intrinsic plasma membrane glyco-
protein containing 13 membrane spanning alpha helices and 
3 N-linked glycosylation sites. NIS is normally located on 
the basolateral surface of thyroid follicular cells and co-
transports two sodium ions down the electrochemical gradi-
ent and one iodide ion up the electrochemical gradient from 
the plasma into the cell. The process is referred to as iodide 
transport, and mutations in NIS are causative for congenital 
iodide transport defects [10, 23, 26]. The iodide transport 
process is driven by energy dependent transport of sodium 
ions through the activity of the Na
+/K
+-ATPase, which is 
also located on the basolateral membrane of the thyroid fol-
licular cell. The main regulator of NIS expression in the thy-
roid is the thyroid stimulating hormone (TSH) [27, 28]. TSH 
stimulation of the TSH receptor initiates a G-protein-
mediated signaling cascade that ultimately results in an in-
crease in NIS mRNA and protein in thyroid follicular cells, 
and regulates the post-transcriptional phosphorylation and 
plasma membrane targeting of NIS [29-33]. 
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TRAPPING AND STORAGE OF IODIDE AND IODI-
NATED MOLECULES IN THE THYROID 
  After iodide is transported by NIS into the cytoplasm of 
the follicular cell, it is either oxidized or it flows down the 
electrochemical gradient to the thyroid lumen (or colloid) 
where, under normal physiological conditions, it is oxidized 
and stored in the form of iodinated tyrosyl residues on thy-
roglobulin for eventual catabolism into thyroid hormones. 
The two-component vectorial transport of inorganic iodide 
from blood to follicular cell cytoplasm to extracellular thy-
roid lumen is referred to as the thyroid trap [34-36] and 
serves as the foundation for the timing of the clinical 
pertechnetate scan, generally performed 20 min post IV in-
jection of 1-5 mCi of 
99mTc04. Quantitative estimates indicate 
that under normal conditions approximately 90% of the thy-
roid 
99mTc04 signal at 20 min is in the extracellular compart-
ment [34-36]. 
99mTc04 is a valuable imaging tool to measure 
this effect since it is efficiently transported by NIS but is not 
oxidized or incorporated into biological molecules and thus 
can resolve the rapid and reversible trapping activity of the 
thyroid from the long-term storage component. There have 
been many reports in the endocrinology and nuclear medi-
cine literature describing molecular imaging techniques to 
distinguish iodide transport, trapping, and storage functions 
in the normal and pathologic thyroid tissue [37-43]. For a 
thorough summary, the interested reader is referred to the 
excellent prospective study by Reshchini et al. [44]. 
ENDOGENOUS NONTHYROIDAL NIS BIODIS-
TRIBUTION AND FUNCTION 
  NIS is also normally expressed in the salivary glands, 
stomach, and lactating mammary glands at levels sufficient 
to visualize these organs with radioiodide if imaging is per-
formed shortly (within a few hours) after administration of 
radioiodide [45]. NIS in the stomach and salivary glands is 
thought to function in an entero-thyroid recirculation loop to 
prolong the retention of iodide prior to renal elimination 
[46], while NIS in lactating mammary glands is thought to 
provide a source of dietary iodide in milk [45]. In addition, 
NIS has been documented, using immunohistochemistry 
and/or reverse-transcriptase polymerase chain reaction (RT-
PCR), in several other human tissues including the lachrymal 
glands, choroid plexus, pituitary gland, ocular ciliary body, 
small intestine, pancreas, adrenal gland, heart, lung, thymus, 
prostate, ovary, kidney tubules, placenta, testis, and rectum. 
With the exception of the small intestine (absorption of io-
dide) and renal tubules (reabsorption of iodide) the physio-
logical role, if any, of NIS in these additional tissues remains 
unknown [3, 47-53]. The primary differences between NIS 
expression and function in nonthyroidal tissues versus its 
role and function in the thyroid gland are that 1) nonthyroi-
dal NIS is not regulated by TSH; rather it appears to be con-
stitutively expressed in most of these other tissues, 2) 
nonthyroidal tissues have no or minimal ability to oxidize 
inorganic iodide to iodine, and 3) nonthyroidal tissues do not 
possess the specific machinery for storage of iodine in the 
form of iodinated compounds. However, like the thyroid 
gland, other tissues which endogenously express NIS (for 
example, stomach and salivary glands) do so in a highly po-
larized fashion, where the fate of NIS-transported iodide is 
secretion down the electrochemical gradient to an adjacent 
extracellular compartment (gastric juice, saliva) opposite the 
pole of NIS expression [54]. 
HETEROLOGOUS NIS IN TUMOR TISSUES 
  In contrast to the two-compartment trapping in the thy-
roid and the two-compartment secretion reaction in other 
tissues which endogenously express NIS, the majority of 
roles for NIS as an imaging transgene are for tumor cells 
which are not polarized. Thus, what is measured in a so-
called iodide uptake assay of non-polarized cells in vitro and 
presumably what is seen on a SPECT image of a NIS-
transduced xenograft is intracellular iodide. Interestingly, 
when directly comparing one-compartment intracellular io-
dide accumulation (in vitro assay), overexpression of NIS in 
a non-thyroidal cell line often results in an even higher mag-
nitude of iodide uptake than that observed in thyroid cell 
lines [55]. This high level of transport activity combined 
with the high density of cells in many tumor types consis-
tently provide a window of sensitivity for the detection of 
NIS-mediated accumulation of radioiodide or 
99mTc04, de-
spite the lack of a second compartment. While the majority 
of reports on the NIS transgene have focused on tumor cells 
and tumor models, a number of recent reports have explored 
its use as a reporter gene or surrogate gene for gene therapy 
and cell trafficking protocols. These normal tissue applica-
tions of NIS add an additional level of complexity to the 
mechanistic study of heterologously-expressed NIS, where 
polarized cells and second compartments could play a role in 
NIS-mediated imaging. 
THE BEGINNING OF NIS AS AN IMAGING RE-
PORTER 
  The NIS gene was first cloned from the rat by Dai et al. 
in 1996 [56]. This was followed by cloning of human NIS 
later that year by Jhiang, et al. [57] and the cloning of mouse 
NIS by Pinke, et al. in 2001 [58]. Transient and stable NIS 
expression in nonthyroidal tissues and tumor xenografts 
stimulates significant iodide uptake in vivo, although to a 
lesser degree than in vitro NIS-mediated uptake, and has led 
to the use of NIS as an imaging reporter in numerous pre-
clinical and two clinical research protocols [7, 55, 59-106].  
 Shimura,  et al. [59] were the first to demonstrate in vivo, 
non-invasive molecular imaging with the NIS transgene. 
While working with FRTL cells (an untransformed, TSH 
dependent, “normal” thyroid epithelial cell line originating in 
Fisher 344 rats) [107], they noted the appearance of a cell 
type with altered morphology, a loss of thyroglobulin ex-
pression, and a reduction in the requirement of exogenous 
TSH beginning at passage 50. These altered cells were 
grown for an additional 40 passages in the absence of TSH 
giving rise to a population of cells (denoted FRTL-Tc) that 
did not require TSH, likely due to compensatory adrenergic 
responsiveness and elevated baseline cAMP. The cells; how-
ever, still responded to TSH. Also, they were no longer sub-
ject to contact inhibition, and were capable of growing as 
syngeneic and metastatic tumors in Fischer 344 rats. This 
was the first report of a malignant thyroid cell line with 
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terization of the cell line revealed that, in addition to loss of 
thyroglobulin, the cells had lost the ability to accumulate 
iodide in an in vitro uptake assay [59]. This prompted the 
investigators to stably transfect the FRTL-Tc line with the 
recently cloned rat NIS gene, which restored in vitro iodide 
transport activity to a level greater than that observed in the 
TSH-stimulated parental FRTL cells. Tumors were then 
grown from these cells in Fischer 344 rats. The rats were 
given a tracer dose of 
125I, and serum and tumor 
125I concen-
trations were determined. A group of animals was anesthe-
tized and serially imaged on a phosphorimaging cassette. 
This allowed the investigators to monitor the time course of 
the appearance and disappearance of radioactivity in the tu-
mor, thyroid, and whole body. Additional rats were eutha-
nized and absolute radioactivity levels were determined ex 
vivo. At peak tracer uptake (2 h post-injection of 
125I) the 
FRTL-Tc-NIS tumors exhibited a mean of 19.3-times the 
serum
 125I concentration and a remarkable 48.3-times the 
control FRTL tumor concentration. Thus, if one assumes a 
uniform concentration of radiotracer and that each tumor cell 
is an independent iodide transporting entity, then one can 
calculate in this model that as few as 5% NIS-expressing 
cells will result in a tumor that appears twice as “hot” as se-
rum. Likewise, using the same 2-fold above background as a 
threshold, only 2% NIS-transduced cells would be required 
to resolve a NIS tumor from a control tumor. These land-
mark studies firmly established NIS as a sensitive and quan-
titative imaging reporter. Mandell (1999) [60] went on to 
document the in vivo visualization of stable NIS-transduced 
melanoma xenografts using 
123I scintigraphy with a clinical 
gamma camera. The following year, Boland et al. (2000) and 
Spitzweg et al. (2000) [4, 55] published imaging results with 
non-replicating adenoviruses encoding NIS in cervical can-
cer, breast cancer, and prostate cancer xenografts. This was 
followed by the engineering of the first replication-
competent oncolytic adenovirus expressing NIS and imaging 
of cervical cancer xenografts and dog prostate [66]. Soon 
after, the first engineered replicating oncolytic RNA virus 
(Edmonston-strain measles virus) expressing NIS (MV-NIS) 
was rescued by Dingli et al. (2004), [108] and images of 
MV-NIS infected myeloma xenografts were presented. 
These pioneering studies paved the way for an explosion in 
the use of NIS as a non-invasive imaging reporter over the 
next decade. 
THE ROLE OF NIS AS AN IMAGING REPORTER 
GENE 
  The three main areas of preclinical and translational re-
search to which NIS reporter imaging has been applied are 
viral-mediated gene therapy, oncolytic viral therapy, and cell 
trafficking (eg, stem cell delivery). Each of these will be 
discussed in further detail. The success of these research 
strategies depends on adequate delivery of the vector or 
transduced/ transfected cell to the target tissue, as well as 
persistent gene expression or viral infection in the target tis-
sue. Noninvasive monitoring of gene expression or viral 
propagation over time in living animals is critical to facilitate 
the advancement of these new molecular therapies in human 
subjects.  
NIS Reporter Imaging in Viral-Mediated Gene Therapy 
Research 
  The NIS reporter has been used for monitoring viral-
mediated cancer gene therapy (defined here as the use of 
viral vectors that are not intended to lyse cells directly, but 
rather require expression of a therapeutic gene). In the vast 
majority of reports in this arena, NIS itself has been em-
ployed as the therapeutic gene with the intention of using 
therapeutic radioisotope concentration as the means of tumor 
ablation. Many of the pioneering studies in this field were 
instrumental in optimizing small-animal imaging method-
ologies that were later applied to all avenues of NIS research 
[4, 6, 55, 59, 64]. However, in these studies the unique rea-
son for imaging was not to report but to “predict” the dose of 
a subsequently administered therapeutic isotope. As dosime-
try is a fundamentally different concept than reporting (do-
simetry requires the area under an imaging curve, and non-
reporter background probe activity is included in the quanti-
tative analysis) it is not the subject of this review. Interested 
readers, however, are referred to several recent reviews on 
the subject [16, 17, 109]. 
  NIS also has been incorporated as an imaging reporter for 
conventional gene therapy protocols. In this context NIS can 
be used as a direct reporter for a gene delivery vector or to 
report on a second therapeutic gene. Niu et al. (2004) [75] 
investigated the use of NIS as a reporter to noninvasively 
image in vivo gene transfer and expression in lung tissue for 
the purposes of developing a gene therapy strategy for cystic 
fibrosis by potentially correcting a mutated CFTR gene and 
restoring its function [75]. These investigators used 
99mTcO4 
scintigraphy and 
124I PET imaging to determine the location, 
magnitude, and duration of pulmonary gene transfer follow-
ing the delivery of Ad-hNIS to the lungs of cotton rats. 
Lungs infected with Ad-hNIS were still visualized at 17 days 
post-instillation of the virus through the rat nostrils. 
  Another recent use of NIS reporter gene imaging has 
been in cardiovascular gene therapy research [83, 110-112]. 
Miyagawa et al. (2005) [110] first demonstrated the feasibil-
ity of NIS for myocardial gene expression imaging in rats 
using 
99mTc04 and 
123I scintigraphy and demonstrated a sig-
nificant correlation between quantitative image analysis and 
ex vivo gamma counting of radioactivity in the NIS trans-
fected hearts. Lee et al. (2005) [83] investigated the accuracy 
of scintigraphy for assessing myocardial gene expression in 
living rats using a dual-gene adenovirus that expressed both 
NIS and eGFP [83]. Results showed increased radioactivity 
uptake in a viral titer-dependent manner, and ex vivo analy-
ses revealed a quantitative relationship between NIS medi-
ated imaging and GFP expression. Rao et al. (2007) and 
Ricci et al. (2008) [111, 112] then went on to demonstrate 
the feasibility of micro-SPECT/CT imaging and quantitation 
of cardiac gene expression after NIS gene transfer in cardiac 
transplants in rats [111, 112]. Ricci et al. also demonstrated 
the high concordance between NIS reporter gene expression 
in the transplanted heart (measured on 
123I scintigraphy) and 
soluble reporter peptide levels in serum using a bicistronic 
adenoviral vector expressing NIS and either human carci-
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NIS Reporter Imaging in Oncolytic Viral Therapy   
Research 
  Because of their ability to selectively replicate and spread 
in cancer cells and their ability to amplify vector-associated 
transgene expression, replication-competent oncolytic vi-
ruses are being used increasingly in cancer therapy [113-
118]. The ability to monitor the delivery and intratumoral 
propagation of oncolytic viruses is critical to understand the 
kinetics of oncolytic viral spread, determine the optimal viral 
dose for safety and maximal therapeutic effect, determine the 
timing of additional therapeutic strategies to enhance the 
oncolytic viral effect, and to improve future oncolytic viral 
design (targeted viruses, etc.). To achieve these goals, onco-
lytic viruses have been modified to express NIS. 
 Barton  et al. (2003) were [66] the first to use NIS as a 
preclinical reporter to monitor and optimize oncolytic virus 
therapy. These investigators used a replication-competent 
adenovirus encoding a yeast cytosine deaminase (yCD)--
herpes simplex virus thymidine kinase (mutTKSR39) fusion 
protein and a second transgene encoding NIS in mouse 
xenograft and dog prostate models. This same group of in-
vestigators went on to publish two additional studies to fur-
ther develop and optimize this adenovirus-mediated therapy 
protocol in small and large animal models [94, 119] and ul-
timately to demonstrate the safety and feasibility of NIS and 
99mTcO4 SPECT/CT as an imaging reporter system in hu-
mans [120, 121].  
 Dingli  et al. (2004) [69] first rescued the recombinant 
Edmonston vaccine strain of measles virus (MV-Edm) en-
coding the NIS gene and demonstrated 1) the ability of MV-
NIS to replicate almost as efficiently as unmodified MV-
Edm, 2) human multiple myeloma tumor cells infected with 
MV-NIS efficiently localized radioiodide in vitro, and 3) 
MV-NIS expressing human myeloma xenografts in immuno-
compromised mice could be visualized in vivo using serial 
123I scintigraphic imaging. Dingli et al. demonstrated the 
ability of 
124I PET/CT to accurately image stably NIS-
transfected and IV MV-NIS infected multiple myeloma 
xenografts [81]. Since these early experiments, other investi-
gators have shown similar results supporting the use of MV-
NIS as an imaging reporter in oncolytic viral therapy studies 
of ovarian cancer, pancreatic cancer, prostate cancer, and 
mesothelioma [88, 103, 122-124]. NIS also has been in-
cluded as a reporter in other oncolytic viruses including ve-
sicular stomatitis virus (VSVDelta51-NIS) [91], a variety of 
oncolytic adenoviruses [66, 92, 106, 125-127], and recently, 
oncolytic vaccinia virus [128]. 
NIS Reporter Imaging in Cell Trafficking Research 
  A further application of the NIS transgene reporter sys-
tem that we will discuss is its use for monitoring the delivery 
and fate of transduced or transfected cells with therapeutic 
capabilities (eg, stem cells, immune cells). Stem cell trans-
plantation is a promising therapeutic option for patients with 
impaired organ function (eg, heart, spinal cord) due to cell 
death; and the use of stem cell therapy in preclinical and 
clinical research is expanding [16, 129-131]. Stem cells are 
pluripotent or omnipotent cells obtained from bone marrow 
and peripheral blood (among other sites in the body) that can 
self-renew and differentiate into specialized cells (including 
tissue-regenerating cells) depending on their microenviron-
ment. Similar to the questions that arise in gene and viral 
therapy research, being able to determine the 1) stem cell 
biodistribution and homing, 2) number of stem cells that 
were successfully engrafted and underwent differentiation, 
and 3) stem cell survival time are critical to the further ad-
vancement of this research field. Thus, reporter genes are 
needed to help track the fate of stem cells in vivo and maxi-
mize the functional benefit of stem cell therapy in patients. 
  Thus far, cell trafficking studies have used in vitro cell 
labeling with either iron oxide nanoparticles (for use with 
MRI imaging) or radionuclides (for use with nuclear medi-
cine imaging modalities) [16, 129-131]. The problem with 
this approach is that it is nonspecific; the imaging signal can 
persist even after death of the labeled cell, impairing the abil-
ity to accurately quantitate successful stem cell engraftment. 
The imaging reporter gene approach can overcome this limi-
tation because the transduced cell will only provide an image 
signal in viable reporter gene-expressing cells.  
  Stem cell therapy is a particularly hot topic in cardiovas-
cular research because of its ability to improve cardiac func-
tion after myocardial infarction [129, 131]. Terrovitis et al. 
(2008) [129] was the first to report the use of NIS to track 
stem cells delivered to the rat heart with SPECT and PET 
imaging. The investigators transduced rat cardiac-derived 
stem cells (rCDCs) using lentiviral vectors and injected them 
intramyocardially (up to 4 million NIS+ rCDCs) immedi-
ately after left anterior descending coronary artery ligation. 
Cell viability and proliferation was not affected by NIS ex-
pression, and 
99mTcO4 SPECT and 
124I PET imaging demon-
strated NIS-mediated uptake of radiotracer in the areas of 
myocardial perfusion deficit. Higuchi et al. (2009) [131] 
used NIS-mediated 
124I PET imaging to successfully monitor 
the delivery and survival of endothelial progenitor cells 
(EPCs) after transplantation into the rat heart (ex vivo myo-
cardial tissue sections confirmed that the 
124I signal was line-
arly related to the number of EPCs present in the heart). 
They also showed that pretreatment of the rat with a combi-
nation of Atorvastatin and VEGF led to a prolongation of 
early survival of the transplanted EPCs. 
  NIS can also be used as a reporter gene for monitoring 
immune cell trafficking in vivo. Seo et al. (2010) [132] pub-
lished the first study using NIS reporter gene imaging to 
monitor macrophage migration towards inflamed tissue 
[132]. These investigators used an immortalized macrophage 
cell line genetically engineered to express NIS and GFP 
(RAW264.7/hNIS-GFP) and small animal PET imaging with 
18F-FDG and 
124I to image an area of chemically-induced 
inflammation in a nude mouse thigh that was created by the 
intramuscular injection of turpentine. The rate of cell prolif-
eration, cytokine production, and phagocytic activity were 
not affected by the insertion of the NIS and GFP dual re-
porter transgenes. PET images obtained with both 
18F-FDG 
and 
124I showed a similar “doughnut-shaped” area of uptake 
at the inflammation/injection site in the rat thigh. The migra-
tion of macrophages to this inflamed site was further con-
firmed by ex vivo IHC staining.  
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THE ADVANTAGES OF MICRO-SPECT AND MI-
CRO-PET FOR NIS IMAGING IN SMALL ANIMALS 
  NIS-mediated transport activity in vivo allows the use of 
standard nuclear medicine imaging modalities including pla-
nar gamma-camera (scintigraphy) and single photon emis-
sion computed-tomography (SPECT) using 
99mTC, 
125I, and 
123I, and positron emission tomography (PET) using 
124I and 
18F-tetrafluoroborate. Prior to the development of dedicated 
small animal imaging systems most preclinical imaging em-
ployed large human clinical systems or laboratory instru-
ments designed for other purposes, such as a phosphorim-
ager. Over the past 10 years, significant advances in instru-
mentation and image reconstruction software have led to the 
development and commercialization of multiple dedicated 
small animal SPECT and PET systems [133-143].  
  Currently, planar scintigraphy is more widely available, 
is less expensive than cross-sectional imaging with SPECT 
or PET, and has been the most widely used imaging modality 
for preclinical NIS research. The planar gamma camera re-
mains a useful tool because it enables the determination of 
the whole-body biodistribution of an injected radionuclide. 
In fact several small animals can be imaged simultaneously 
due to the large field of view afforded by the gamma camera. 
However, the planar gamma camera has considerable limita-
tions due to its low resolution and because it represents a 3-D 
distribution of radioactivity in a 2-D display [144, 145]. This 
results in superimposition of overlying radioactivity, diffi-
culty with accurate localization of abnormalities, and errors 
in radiotracer quantitation [146]. In addition to these general 
problems, there are also potential challenges with the NIS 
reporter for in vivo planar scintigraphy with radionuclide-
based techniques because of high radiotracer uptake in the 
stomach that may result in a strong signal on the 2-D scinti-
graphic images. This may lead to decreased spatial resolution 
and inaccurate monitoring of NIS  expression in adjacent 
abdominal organs such as the liver, spleen, and pancreas.  
  Cross-sectional imaging techniques such as SPECT and 
PET are needed to improve 3-D spatial resolution and sepa-
rate the overlapping regions of radioiodine uptake in vivo. 
Combined multi-modality scanners have recently been de-
veloped that allow fusion of functional (SPECT or PET) data 
with high-resolution anatomical (CT) data to provide a more 
accurate localization and quantitative estimate of radioactiv-
ity in live animals. A tri-modal small-animal PET/SPECT/ 
CT system was also recently introduced [141].  
  Although PET is more often used than SPECT for clini-
cal applications because of its higher sensitivity, resolution, 
and quantitative advantages for deep-tissue imaging, this is 
not the case for small animal imaging. There are several ex-
cellent recent review articles comparing the advantages and 
disadvantages of micro-SPECT and micro-PET imaging in 
preclinical research [141, 143, 147-149]. Briefly, micro-
SPECT and micro-PET both use similar detector systems 
and record the emission of photons in vivo to document the 
location of an administered radiotracer. The type of decay 
that each of the system detects, however, is different (single 
gamma photon emission for SPECT versus two photon emis-
sion from positron annihilation for PET) and therefore re-
quires the use of different radionuclides.  
  Two of the biggest differences between small animal 
SPECT and PET are with regard to image sensitivity and 
resolution. SPECT imaging requires the use of a lead colli-
mator to detect and convey information about the origin and 
direction of the gamma photon for representation in a 3-
dimensional image format. Because lead collimators reject 
the majority of emitted gamma photons (>99%), the sensitiv-
ity of SPECT is approximately 2 orders of magnitude lower 
than PET and therefore requires higher doses of administered 
radiotracer and/or increased imaging time [143, 147, 148]. 
Cheng  et al. (Cheng 2010) compared two commercially 
available small animal SPECT and PET imaging systems 
with regard to image sensitivity and resolution by imaging a 
mouse flank xenograft using 
99mTc04 and 
18F-labeled tumor-
specific nanoparticles. Their results demonstrated 15-fold 
higher sensitivity with PET for detection of tumor radioac-
tivity. The trade-off, however, is that SPECT can employ 
multiple pinhole collimators to provide higher spatial resolu-
tion than PET (down to < 0.5 mm for micro-SPECT versus 1 
to 2 mm for micro-PET) [143, 148]. Marsee et al. [74] were 
the first to image NIS expression with micro-SPECT/CT and 
were able to detect NIS-expressing orthotopic lung tumors as 
small 3 mm with 
125I micro-SPECT using pinhole collima-
tion. Newer generation micro-SPECT systems offer sub-
millimeter image resolution with increased sensitivity using 
a detector with a larger surface area and increased field-of-
view [138, 140]. Targeted pinhole micro-SPECT can also be 
used to increase SPECT imaging sensitivity [142] within a 
small field of view. 
  Several researchers have used 
124I PET imaging to docu-
ment  in vivo NIS expression [65, 71, 75, 81, 128, 150]. 
Groot-Wassink,  et al. showed a strong correlation (r = 
0.9581) between PET imaging quantitation (%ID/g) and ex 
vivo analysis of 
124I hepatic uptake in mice systemically ad-
ministered a NIS-expressing adenovirus [71]. Dingli, et al. 
[81] used a clinical PET/CT scanner to document and quanti-
tate NIS-mediated 
124I uptake in stable NIS-expressing (25% 
ID) and MV-NIS infected (7.1%) mouse myeloma 
xenografts. The drawbacks associated with use of 
124I are 
that it is not readily available, its production is complex, and 
the tissue penetration prior to annihilation of the high energy 
positrons from 
124I decay (maximum positron range of >6 
mm) severely limits the spatial resolution in a small animal 
setting [151]. A recent breakthrough in NIS research is the 
development of a novel PET probe 
18F-tetrafluoroborate 
([
18F]TFB) [152, 153]. Although not yet widely used, this 
may replace the less sensitive and lower resolution 
124I for 
PET imaging of NIS.  
  In addition to image sensitivity and resolution, there are 
several other factors to consider with regard to choosing an 
imaging modality for NIS. Advantages of SPECT compared 
to PET for small animal studies are that SPECT is 1) less 
expensive, 2) able to image multiple probes labeled with 
different radiotracers of different energies at one time allow-
ing the visualization of more than one molecular event, 3) 
ability to use radiotracers that are readily available at on-site 
pharmacies and that do not require an on-site cyclotron for 
production. However, both micro-SPECT and micro-PET 
can provide similar highly accurate in vivo quantitation of 
radioactivity and have been thoroughly validated by direct 
comparison with ex-vivo analyses [71, 84, 122, 136, 143]. 38    Current Gene Therapy, 2012, Vol. 12, No. 1  Penheiter et al. 
RELATIONSHIP BETWEEN IMAGING ACTIVITY 
AND FRACTION OF NIS-EXPRESSING CELLS 
  Ultimately the result of quantitative imaging can be 
viewed as a concentration (some measure of atoms or activ-
ity per unit of mass or volume). In molecular imaging this is 
often referred to as absolute quantitation. The term “absolute 
quantitation” helps to distinguish it from other forms of im-
age quantitation that are relative to internal or external con-
trols in either a spatial or temporal manner. From the concen-
tration value obtained from imaging, with appropriate valida-
tion experiments, it is then possible to calculate the fraction 
or number of NIS-expressing cells within a given volume. It 
is important to note here that thyroid quantitation is funda-
mentally different in this regard. The results of quantitative 
thyroid image analysis are usually presented as % injected 
dose with no denominator. The reasons for this are 1) the 
ability of the thyroid to compete with all other forms of ra-
dioiodide tracer clearance  in the body is an important 
physiological property of the gland, and 2) when concentra-
tion is required (such as in dosimetry calculations), a stan-
dard organ mass is often used.  
  In theory, both CT and SPECT (or PET) are absolutely 
quantitative because imaging instruments are calibrated with 
standards so the reconstructed CT dimensions and SPECT or 
PET voxel (a volumetric or three-dimensional pixel) inten-
sity exactly match the true dimensions and true radionuclide 
concentration within the voxel. In humans, however, attenua-
tion of photons and Compton scatter result in considerable 
loss of photons reaching the detector in comparison to in-
strument calibration standards where the surrounding me-
dium is air. 
  In mice, with medium energy photons such as those from 
99mTc decay (140 keV) or positron annihilation (511 keV), 
attenuation and scatter losses are minimal. However, a dif-
ferent impediment to accurate quantitation is encountered—
the resolution of small animal micro-SPECT/CT or micro-
PET/CT devices is much lower than human SPECT/CT or 
PET/CT relative to anatomical volume. Thus, large correc-
tions are required for partial volume effects, where the ma-
jority of counts are projected (displayed) outside of the vol-
ume from which they emanated. With a spherical tumor of 
uniform activity, this partial volume effect can be corrected 
for based on standard curves generated from imaging spheri-
cal phantoms of known dimension and activity Fig. (1) [84]; 
however, for different shaped tumors and non-uniformly 
distributed signals, deviations from the standards are often 
too large to provide accurate quantitative data.  
  Additionally, at the CT settings typically employed for 
small animal imaging, [84, 103] even subcutaneous tumors 
are only weakly resolved from underlying skeletal muscle, 
surrounding fluid, and overlying skin. These difficulties in 
small animal SPECT/CT and PET/CT have resulted in a 
general bias where tumors for quantitative imaging studies 
are often much larger than those employed for therapy stud-
ies in the same model. In a recent paper [122], we attempted 
to address these issues by using 1) 1-mm pinhole SPECT 
collimation, 2) SPECT-based volume of interest (VOI) 
analysis, 3) empirical tumor-based CT optimization for accu-
rate measurement of in vivo subcutaneous tumor dimensions, 
and 4) tumor volumes that are more typical of established 
tumor models for therapy (0.1 to 0.6 cm
3). We directly com-
pared the in vivo imaging measurements to ex vivo measure-
ments immediately following imaging. Fig. (2) Using a 
threshold of 1.5-fold above control tumor uptake (back-
ground), we calculated 2.7% MV-NIS-infected BxPC-3 tu-
mor cells were required for detection within this model. Ad-
ditionally, by measuring the volume of BxPC-3 tumor cells 
and the tumor cell/stroma ratio, we can calculate that with 
the imaging settings employed (2.2 mm voxel size), ap-
proximately 2 x 10
5 infected tumors cells are required to 
reliably resolve a zone of infection from background in this 
model Fig. (3). We have applied the same general techniques 
to orthotopic pancreatic tumors stably expressing NIS   
Fig. (4), and to document multiple sites of MV-NIS injection 
and infection within a single flank tumor Fig. (3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). A spherical phantom study to determine the partial volume losses on a Gamma-Medica (Northbridge, CA) X-SPECT System. Im-
ages for the 
99mTcO4 phantom series were obtained with a high-sensitivity parallel-hole collimator and a 1-mm pinhole collimator. The frac-
tion of counts displayed within CT defined spheres is plotted as a function of sphere volume. 
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Fig. (2). Pinhole micro-SPECT/CT image analysis versus ex vivo quantitation of BxPC-3 tumors 3 days post-infection with an oncolytic mea-
sles virus encoding NIS. A single spherical volume of interest (VOI) was drawn around each tumor and the activity determined with PMOD 
imaging software. Immediately following imaging, tumors were excised and counted in a dose calibrator.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Micro-SPECT/CT image and corresponding immunohistochemistry analysis of early infection with multiple intratumoral injections 
of MV-NIS. A BxPC-3 xenograft was injected in three locations with a total dose of 3.5 x 10
6 MV-NIS. On day 4 post-injection, the animal 
was imaged with pinhole micro-SPECT/CT. (A) The tumor was removed, aligned with the micro-SPECT/CT image, processed by IHC for 
measles N (brown staining), and counterstained with hematoxylin. (B) An excellent spatial correlation is seen between the live animal micro-
SPECT/CT image and the three small zones of intratumoral infection. 
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Fig. (4). Micro-SPECT/CT imaging of an orthotopic transplantation model of pancreatic cancer. BxPC-3-NIS xenograft fragments were 
transplanted to the pancreas of donor mice. Twenty days after transplantation, animals were injected with 1 mCi 
99mTc04 and imaged 1 h later. 
(A) Coronal fusion micro-SPECT/CT slice through the center of the pancreatic tumor (arrow) adjacent to the endogenous stomach activity 
(arrowhead). Thyroid uptake is also seen on the image. (B) The same imaging data set is displayed as a maximum intensity projection (MIP) 
generated from threshold-adjusted axial slices. (C) Post-mortem analysis reveals the size and location of the pancreatic tumor (arrow) relative 
to adjacent stomach (arrowhead) and other organs.  
 
  A number of other reports have demonstrated the ability 
of the NIS transgene to serve as an absolute quantitative re-
porter for gene therapy vectors. Groot-Wassink et al. (2004) 
[71] performed a study with a non-replicating adenoviral 
vector expressing a CMV promoter-driven NIS (Ad-hNIS). 
They administered increasing doses of Ad-hNIS (5 x 10
6 to 
2.5 x 10
9 pfu) to C57/B6 mice via tail vein injection. To 
validate the quantitative reporter aspects of the transgene, an 
ex-vivo comparison of NIS-mediated 
124I accumulation and 
NIS RNA (as a surrogate for infected cells) was performed. 
The results indicated a nearly perfect correlation between 
124I 
quantitation and NIS RNA in both the threshold dose to es-
tablish a significant infection and linearity with increasing 
dose above the threshold. Subsequent IHC analysis of mouse 
liver sections enabled an estimate of the relationship between 
124I concentration, quantitative RNA analysis, and percent of 
cells infected with virus. Further experiments were per-
formed to confirm the in vivo quantitative analysis with 
124I 
PET. A nearly perfect linear correlation was confirmed be-
tween volume of interest image analysis and ex vivo meas-
urements of radiotracer uptake. In this example, the liver is 
quite large relative to the resolution of the imaging system 
and a uniform distribution of IV administered Ad-hNIS 
within the liver can be assumed. Therefore, the conversion of 
imaging “activity” to a meaningful measure of absolute con-
centration (% ID/g) is straightforward. In a similar study, 
Lee and Kim et al. (2005) [83] assessed infection in living 
rats following intramyocardial injection of an adenovirus 
expressing NIS and eGFP [83]. As in the Groot-Wassink 
study, a threshold dose of Ad-GFP-NIS was required to es-
tablish a quantifiable infection. Beyond that, however, there 
was a very good correlation between % ID/g (following ad-
ministration of 
123I) and the measurement of quantitative 
fluorescence for GFP content in the transduced cardiac tis-
sue. 
  A fundamentally different form of quantitative reporter 
use of NIS was tested in a study by Vadysirisack et al. 
(2006) [154]. The authors attempted to determine the utility 
of NIS as a gene/promoter reporter. They used quantitative 
immunoblotting, RNA analysis, and a tetracycline-inducible 
promoter to drive a gradient of NIS expression. This enabled 
a direct comparison between NIS mRNA levels, total NIS, 
surface NIS, and iodide transport activity in a synchronized 
manner. They observed in several different cell types a level 
of NIS surface protein above which additional steady iodide 
transport activity did not occur. This non-linear relationship 
between NIS mRNA, NIS protein, and NIS activity, indi-
cates that NIS is probably not an ideal candidate reporter for 
a gene/promoter assay.  
  Conditionally-replicating adenovirus (CRAds) may rep-
resent the most difficult challenge to the concept of NIS re-
porter quantitation of transduction. With CRAds there may 
be a clear virion per cell (gene dose) response at early time 
points or if the cells are minimally permissive to amplifica-
tion. While in other cells, a region of low MOI infection 
combined with substantial amplification could result in a 
similar imaging signal as a high MOI infection. In order to 
deal with these practical issues, Barton et al., [66, 119, 121] 
introduced the concept of gene expression volume (GEV, 
with units of cm
3) and the gene expression unit (GE, which 
equals the GEV times the ratio of imaging intensity in the 
SPECT/CT fusion SPECT/CT 3D MIP Post-mortem
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GEV to that of blood). For example, a region of interest sig-
nal of 1 cm
3 with a mean calculated probe concentration of 3 
times that of the blood would equal 3 GE units. These units 
could then serve as reference values for optimization of in-
tratumoral injections where the combined volume of NIS 
activity and magnitude of NIS activity should reflect the total 
tissue dose of drug produced from a prodrug convertase en-
coded in the same virus. In a phase 1 clinical trial extension, 
Barton et al. 2011 [121] used a replication-competent adeno-
virus encoding a yeast cytosine deaminase (yCD)--herpes 
simplex virus thymidine kinase (mutTKSR39) fusion protein 
and a second transgene encoding NIS (Ad5-yCD/ 
mutTKSR39rep-hNIS). They directly injected 5 x 10
12 Ad5-
yCD/mutTKSR39rep-hNIS viral particles divided into twelve 
injection sites into the prostate of 6 patients with localized 
prostate cancer. The patients were imaged serially with 
SPECT/CT after intravenous injection of 
99mTc04 beginning 
one day after administration of the virus. Quantitative 
SPECT/CT image analysis enabled the determination of 1) 
the volume of Ad5-yCD/mutTKSR39rep-hNIS infected pros-
tate, 2) the concentration of 
99mTc within each GEV and it’s 
relation to adjacent organs and blood, 3) the % of prostate 
infected, and the 4) the rate of disappearance of infection 
from the prostate.  
RADIONUCLIDE BASED REPORTER/PROBE SYS-
TEMS 
  Radionuclide-based reporter imaging techniques with 
scintigraphy, SPECT, or PET offer the highest sensitivity for 
detecting low levels of reporter gene expression (picomolar 
sensitivity) and appear the most suited for translation to the 
clinic at this time [1, 2, 155, 156]. Optical imaging tech-
niques (with bioluminescent enzyme/substrate systems or 
fluorescent proteins) are useful in small animals, but are lim-
ited in humans due to the depth of tissue penetration (gener-
ally < 2cm) [157]. Magnetic resonance imaging with specific 
contrast agents offers high spatial resolution [158-160] but is 
less sensitive than radionuclide techniques and is limited by 
the high concentration of contrast material required to pro-
vide sufficient image contrast [161].  
  In addition to NIS, several other radionuclide based re-
porter systems have been utilized for preclinical and transla-
tion studies. Table 1 contains a list of these reporter proteins, 
along with some of the commonly employed SPECT and 
PET probes for each reporter. Radiological (physical) half-
life, positron yield, maximum positron energy for PET iso-
topes, and the principle ‘imageable” gamma photon for 
SPECT isotopes are given for each radionuclide. Herpes 
simplex virus-1 thymidine kinase (TK) and an optimized 
mutant (sr39tk), which has higher affinity for imaging probes 
and lower affinity for thymidine, can be imaged with radio-
labeled acycloguanosines or 2’-fluoro nucleoside analogs of 
thymidine. The Dopamine D2 receptor (DR2) and a second 
generation receptor (R80A), which retains ligand binding 
function but does mediate internal signaling, can be imaged 
with 
11C, 
18F, or 
123I-labeled D2 antagonists. Likewise, a va-
riety of somatostatin analogs are available for either PET or 
SPECT imaging of the somatostatin receptor type 2 
(SSRT2). The norepinephrine transporter (NET) can be im-
aged with either 
123I or 
124I MIBG (a norepinephrine analog). 
Radionuclide probes for NIS are either radioactive isotopes 
of iodide (
123I, 
124I, 
125I), or molecules with a size and charge 
density similar to iodide, such as 
99mTc04 or [
18F]-TFB. 
NIS VERSUS OTHER SPECT/PET REPORTERS 
  As can be seen in Table 1, all of the commonly employed 
radionuclide reporters can be imaged with either PET or 
SPECT probes. Thus, the decision to choose one reporter or 
another can be made largely upon biological considerations 
rather than on the basis of instrumentation. Some biological 
considerations when choosing a reporter/probe system are 
(1) endogenous receptor activity, background localization of 
probe, location of target tissue in relation to regions of high 
probe concentration, and the timing and potential competi-
tion of endogenous activity and background in relation to the 
desired reporter signal. In this regard, NIS would not be de-
sirable for a reporter in the stomach or bladder. However, the 
low background of NIS probe activity in liver, kidney, or 
skeletal muscle for example might be ideal for NIS imaging. 
(2) For conventional gene therapy approaches, it is desirable 
to use a self-protein as a reporter to minimize the possibility 
of immune-mediated destruction of cells encoding the re-
porter. An advantage of NIS is this regard is that in addition 
to being a self-protein, NIS-encoding constructs from several 
species including mouse, rat, human, and dog (Stephen J. 
Russell, unpublished), have been developed and tested in 
animals. (3) Also, for conventional gene therapy, it is impor-
tant to consider biological activity of the ectopically ex-
pressed reporter and its effect on cell physiology (either con-
stitutive activity or through the action of endogenous sub-
strates). These issues have been addressed for HSV-1 TK 
and D2R with the engineering of vectors encoding the sr39tk 
mutant and R80A mutant, respectively [155, 162]. Theoreti-
cally, constitutive activity might be a concern for NIS. How-
ever, long term culturing of stable NIS expressing cells lines, 
as well as long term expression of NIS in normal animal 
tissue, for example, in the NIS transgenic heart mouse [163], 
would seem to indicate that most cells are quite able to toler-
ate a background level of NIS activity. (4) A final biological 
consideration is the size of the reporter gene—the vector 
must be able to accommodate the insert. In this respect, NIS 
is the largest of the reporters, which could limit its applica-
tions in some viruses with strict limits on insert size.  
  If these biological considerations above are met, the pri-
mary advantage of NIS is that it can be used with inexpen-
sive and readily available 
99mTcO4. 
99mTcO4 costs only a few 
dollars per dose and can be eluted daily from an in-house 
generator. No labeling reactions are required, and the imag-
ing characteristics (140 keV gamma) are ideal and standard-
ized for quantitative SPECT/CT imaging in both small ani-
mal and human instruments. A disadvantage of NIS versus 
some other commonly employed reporters is that the only 
approved PET isotope for NIS imaging is 
124I. The high en-
ergy positrons released from 
124I decay have a long range in 
tissue prior to annihilation, which limits resolution, and the 
yield of positrons from 
124I is quite low relative to several 
other PET isotopes [164-166]. It remains to be seen if [
18F]-
TFB will be approved for human use. However, if approved, 
[
18F]-TFB should provide the ideal combination of sensitiv-
ity (four 
18F atoms per molecule) and resolution for PET 
imaging of the NIS reporter. 42    Current Gene Therapy, 2012, Vol. 12, No. 1  Penheiter et al. 
Table 1.  Heterologous Reporter/Probe Imaging Strategies 
Reporter  Probe  Modality  Half-life  Positron (yield), Energy  References 
Dopamine D2 Recep-
tor 
(R80A) 
 
443 aa 
[
11C]raclopride 
 
3-(2-[
18F]fluoroethyl)-spiperone 
 
[
123I]iodobenzamine 
PET 
 
PET 
 
SPECT 
20 min  
 
110 min 
 
13.3 h 

+ (100%), 0.96 MeV 
 

+ (97%), 0.635 MeV 
 
, 159 keV 
[162, 167-
171] 
Herpes Simplex Virus-
1 Thymidine Kinase 
(sr39tk) 
 
 
376 aa 
9-[4-[
18F]fluoro-3-(hydroxymethyl)butyl] 
guanine ([
18F]FHBG) 
 
1-(2-deoxy-2-[
18F]fluoro-D-arabinofuranosyl)-
5-iodouracil ([
18F]FIAU) 
 
1-(2-deoxy-2-fluoro-D-arabinofuranosyl)-5-
[
124I]iodouracil([
124I]FIAU) 
 
[
125I]FIAU 
 
[
18F]-2-Fluoro-2deoxy-1h-D-
arabionofuranosyl-5-ethyl-uracil ([
18F]FEAU) 
PET 
 
 
PET 
 
 
PET 
  
  
SPECT 
  
PET 
110 min 
 
 
110 min 
 
 
4.2 days 
  
  
59 days 
  
110 min 

+ (97%), 0.635 MeV 
 
 

+ (97%), 0.635 MeV 
 
 

+ (25%),  2.13 MeV 
  
  
, 35 keV 
  

+ (97%), 0.635 MeV 
[77, 155, 
172-180] 
Somatostatin Receptor  
Type 2 
 
369 aa 
111In-octreotide 
 
 
99mTc-octreotide 
 
 68Ga-dotatate 
 
94mTc-demotate-1  
SPECT 
 
SPECT 
 
PET 
 
PET 
2.8 days 
 
6 h  
 
68  min 
 
53 min 
, 171, 245 keV 
 
, 144 keV 
 

+ (90%), 1.90 MeV 
 

+ (72%), 2.47 MeV 
[181-186] 
Norepinephrine Trans-
porter  
 
617 aa 
meta[
123I]iodobenzyl- 
guanidine ([
123I]MIBG) 
 
meta[
124I]iodobenzyl- 
guanidine ([
124I]MIBG) 
SPECT 
 
 
PET 
13.3 h 
 
 
4.2 days 
 
, 159 keV 
 
 

+ (25%), 2.13 MeV 
[187-190] 
Sodium Iodide Sym-
porter 
 
643 aa 
99mTc04 
 
123I 
 
125I  
 
124I  
 
[
18F]tetrafluoroborate 
SPECT 
 
SPECT 
 
SPECT 
 
PET 
 
PET 
6 h  
 
13.3 h 
 
59 days 
 
4.2 days 
 
110 min 
, 140 keV 
 
, 159 keV 
 
, 35 keV 
 

+ (25%) 2.13 MeV 
 

+ (97%), 0.635 MeV 
[55, 59, 60, 
62, 65, 152, 
153, 191] 
Legend: R80A refers to Arg to Ala substitution at residue 80;  
sr39tk is a thymidine kinase mutant with increased activity against acycloguanosines;  
, gamma photon, 
+, positron. 
 
CONCLUSIONS 
  As indicated throughout this review, the desirable attrib-
utes of NIS are its quantitative nature, its remarkable flexi-
bility of iodide transport activity in many cells types using 
viral and non-viral platforms, and the ease in which the ac-
tivity is observed in vivo. The main hurdle to the use of NIS 
transgene and all other reporter-based technology is the sen-
sitivity (the concentration of probe within the target region 
versus that in the plasma or neighboring region). Sensitivity 
is of particular concern for oncolytic virotherapy research   
 
using replicating viruses where it is desirable to detect lower 
levels of infection that may cause unwanted side effects, and 
for situations where the goal is to obtain “proof of concept” 
information in a model that may not be a “best case sce-
nario”. The hope is that with continued work in basic re-
search to improve sensitivity, validation in relevant animal 
models, and ultimately translation to human clinical trials, 
we will see a time when the concept of imaging reporter-
guided gene therapy, viral therapy, and cell-based therapy 
becomes a standard of care for diseases which today are un-
treatable.  The Sodium Iodide Symporter (NIS) as an Imaging Reporter for Gene, Viral, and Cell-based Therapies  Current Gene Therapy, 2012, Vol. 12, No. 1    43 
  Additionally there is hope that in the future reporter gene 
imaging will facilitate more than simply accurate reporting 
on the spatial and temporal pattern of vectors. It is conceiv-
able that the results of reporter imaging will both serve as a 
guide for confirmatory biopsies and enable clinicians to 
make rational decisions about additional or complementary 
therapies on a patient-by-patient basis  
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